- Home
- GDO vs SERA Comparison
GDO vs SERA Comparison
Compare GDO & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GDO | SERA |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.2M | 75.2M |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GDO | SERA |
|---|---|---|
| Price | $10.26 | $2.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 33.0K | ★ 34.3K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $554.81 |
| Revenue Next Year | N/A | $517.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $10.20 | $1.56 |
| 52 Week High | $12.15 | $3.95 |
Technical Indicators
Market Signals| Indicator | GDO | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 28.57 | 52.57 |
| Support Level | N/A | $1.68 |
| Resistance Level | $10.86 | $2.40 |
| Average True Range (ATR) | 0.08 | 0.19 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 11.11 | 47.24 |
Price Performance
Historical ComparisonAbout GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.